You just read:

Less Than 30 Percent of Surveyed Relapsing-Remitting Multiple Sclerosis Patients in the U.S. Would Request a Switch to an Agent With Dosing, Safety and Efficacy Similar to Emerging and Recently Launched Oral Agents

News provided by

Decision Resources

Dec 01, 2010, 10:36 ET